How to Get NMN/NR (Nicotinamide Mononucleotide/Riboside) in Montana

Montana's Regulatory Framework for NMN/NR Prescribing

Montana permits telehealth prescribing of compounded medications, including NAD+ precursors like NMN and NR, provided the prescriber holds an active license recognized by the Montana Board of Medical Examiners or the Montana Board of Nursing. No in-person visit is required for the initial consultation.

The Montana Code Annotated (MCA) Title 37, Chapter 3 governs medical practice in the state, and the 2023 telehealth parity statute (SB 101) confirmed that prescriptions issued via synchronous audio-video visits carry the same legal weight as those from office encounters. This means a physician in Billings, Missoula, or any other Montana city can evaluate a patient remotely and send a prescription to a compounding pharmacy the same day.

NMN and NR are not FDA-approved drugs. They exist in a regulatory gray zone. The FDA issued a public statement in November 2022 indicating that NMN may not qualify as a dietary supplement because it was first investigated as a new drug. This determination pushed many consumers toward the prescription compounding pathway, which operates under Section 503A of the Federal Food, Drug, and Cosmetic Act. Under 503A, a licensed pharmacist may compound NMN or NR for an individual patient based on a valid prescription [1].

Yoshino et al. demonstrated in a 2021 randomized controlled trial (N=25 postmenopausal women with prediabetes) that 250 mg/day oral NMN for 10 weeks improved skeletal muscle insulin sensitivity by approximately 25% compared to placebo [2]. This trial remains one of the few human RCTs supporting NMN supplementation.

Who Can Prescribe NMN/NR in Montana

Any provider with prescriptive authority under Montana law can write an NMN/NR prescription. That category includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs).

Montana NPs gained full practice authority in 2023 under HB 227. They do not require a collaborative agreement with a physician to prescribe. PAs still practice under a supervising physician's delegation agreement per MCA 37-20-401, but this does not restrict their ability to prescribe compounded NAD+ precursors as long as the supervising physician's scope permits it.

Telehealth platforms specializing in longevity medicine are the most common access point for Montana residents. These platforms typically employ physicians licensed in multiple states, including Montana, and they handle the prescription routing to partnered 503A pharmacies automatically.

The prescriber must document a clinical rationale. Common documented indications include age-related NAD+ decline, metabolic optimization, and cellular energy support. A 2020 systematic review in Translational Medicine of Aging noted that NAD+ levels decline by roughly 50% between ages 40 and 60, providing the biological foundation for supplementation [3].

Required Labs Before Starting NMN/NR

Most telehealth providers require baseline bloodwork before prescribing NMN or NR in Montana. The standard panel includes a comprehensive metabolic panel (CMP), complete blood count (CBC), fasting lipid panel, and fasting glucose or HbA1c.

Some longevity-focused clinicians also request NAD+ metabolite testing, though this is not universally required. Intracellular NAD+ assays (offered by labs like Jinfiniti) cost $150 to $300 out of pocket and are not covered by Montana Medicaid or most private insurers.

Liver function tests (AST, ALT) within the CMP are particularly relevant. A 2022 study published in the Journal of Clinical Endocrinology & Metabolism confirmed that oral NR at 1 to 000 mg/day for 12 weeks raised hepatic NAD+ without elevating liver transaminases in overweight adults [4]. Providers monitor these markers to confirm safety throughout treatment.

Montana has over 60 Quest Diagnostics and Labcorp draw sites. Patients in rural areas (Glacier County, Garfield County, or other low-density regions) can use mobile phlebotomy services or ship-to-lab finger-prick kits accepted by many telehealth longevity platforms.

Labs from the prior 60 to 90 days are typically accepted. If you already have recent bloodwork from a primary care visit, most prescribers will use those results without requiring a repeat draw.

The 503A Compounding Pharmacy Pathway

Once a Montana-licensed provider writes the NMN/NR prescription, it goes to a 503A compounding pharmacy. These pharmacies operate under federal exemption and must hold both a home-state license and comply with Montana Board of Pharmacy regulations for shipping into the state.

Montana does not require a separate "non-resident pharmacy" registration for 503A facilities shipping patient-specific compounds, as long as the pharmacy is licensed in its own state and fills only individual prescriptions (not bulk manufacturing). This differs from some states that mandate non-resident pharmacy permits.

Commonly compounded forms include:

• Oral capsules (NMN 250 mg, 500 mg, or 1 to 000 mg)
• Sublingual tablets (NMN 125 mg or 250 mg for faster absorption)
• NR capsules (300 mg or 500 mg)
• Combined NMN + TMG (trimethylglycine) capsules

Sublingual formulations bypass first-pass hepatic metabolism. A 2023 pharmacokinetic study in GeroScience showed that sublingual NMN raised plasma NMN levels 2.3-fold higher at 30 minutes compared to oral capsules of the same dose [5]. Some Montana providers preferentially prescribe sublingual forms for this reason.

Timeline: Consultation to Delivery in Montana

The entire process from initial telehealth visit to receiving your NMN/NR shipment typically spans 5 to 10 business days for Montana addresses.

Day 1: Complete the telehealth intake form and upload labs. Day 1 to 3: Provider reviews records and conducts a synchronous video consultation (usually 15 to 20 minutes). Day 3 to 5: Prescription sent to compounding pharmacy; pharmacy compounds the formulation. Day 5 to 10: Shipment via USPS Priority or FedEx to your Montana address.

Rural Montana addresses (zip codes beginning with 592, 593, 594, 595) may add 1 to 2 transit days due to limited carrier routing. Addresses in Missoula, Billings, Great Falls, Helena, and Bozeman typically receive packages on the faster end of that window.

Cold-chain shipping is not required for NMN or NR capsules. Both molecules are stable at room temperature for at least 12 months when stored below 77°F, per USP <795> standards for non-sterile compounding [6].

Cost and Insurance Coverage in Montana

Montana Medicaid does not cover NMN or NR. No private insurer in Montana currently covers NAD+ precursors either, as these compounds lack FDA approval for any specific indication.

Out-of-pocket costs break down as follows:

• Telehealth consultation: $99 to $250 for the initial visit; $49 to $150 for follow-ups
• Compounded NMN (30-day supply, 500 mg/day): $75 to $180
• Compounded NR (30-day supply, 300 mg/day): $60 to $150
• Lab work (if not covered by insurance): $50 to $300 depending on panel breadth

Total first-month cost for most Montana patients ranges from $225 to $500. Subsequent months drop to $75 to $200 for the compound alone plus periodic follow-up visits (typically quarterly).

HSA and FSA accounts may reimburse prescription compounded NMN/NR if the prescription is documented with a Letter of Medical Necessity. Montana has no state-level restriction on HSA/FSA use for compounded prescriptions.

NMN vs. NR: Which NAD+ Precursor to Choose

Both NMN and NR raise intracellular NAD+ levels. They enter the salvage pathway at slightly different points, but the clinical distinction for patients is minimal based on current evidence.

NR (nicotinamide riboside, marketed as Niagen in supplement form) has more published human clinical trial data. A 2018 trial by Martens et al. (N=24) published in Nature Communications showed that NR 1 to 000 mg/day for 6 weeks raised whole-blood NAD+ by 60% and reduced systolic blood pressure by 5 mmHg in healthy older adults [7].

NMN has fewer completed human trials but growing data. The Yoshino 2021 trial [2] is the most rigorous to date. A 2022 Chinese RCT (N=66 healthy adults, 40 to 65 years) published in GeroScience found that 300 mg NMN twice daily for 60 days improved 6-minute walk distance by 51 meters versus placebo [8].

The choice between NMN and NR often comes down to prescriber preference and patient response. Some Montana telehealth providers offer both and switch patients based on 8-week follow-up labs.

Transferring an Existing NMN/NR Prescription to Montana

If you already have an NMN/NR prescription from another state, Montana law permits prescription transfers for compounded medications, provided the receiving pharmacy is licensed to ship to Montana.

The process works in one of two ways. First, your existing compounding pharmacy may already ship to Montana addresses. Call and confirm. Second, if you need a new pharmacy, your prescribing provider can send a new prescription to a Montana-compatible 503A pharmacy.

One constraint: 503A prescriptions are patient-specific. They cannot be "transferred" in the same way a retail prescription for a manufactured drug transfers between CVS locations. The prescriber must issue a new prescription to the new pharmacy. This is typically handled with a brief chart note or phone call, not a full re-evaluation.

If your prescriber is not licensed in Montana, you will need a new provider. Telehealth platforms make this straightforward since many maintain panels of providers licensed in 40+ states, Montana included.

Safety Monitoring and Follow-Up Protocols

Standard follow-up for NMN/NR prescriptions in Montana involves labs at 8 to 12 weeks after initiation, then every 6 months. The repeat panel mirrors baseline: CMP, CBC, lipid panel, fasting glucose.

Adverse effects reported in clinical trials have been mild. The Yoshino 2021 trial reported no serious adverse events at 250 mg/day [2]. The Martens 2018 NR trial at 1 to 000 mg/day reported mild GI symptoms (nausea, bloating) in 3 of 12 participants on NR versus 1 of 12 on placebo [7].

One theoretical concern is the effect of chronic NAD+ elevation on cancer biology. NAD+ is required for DNA repair but also fuels rapidly dividing cells. A 2020 review in Cell Metabolism noted that no human trial to date has shown increased cancer incidence with NR or NMN supplementation at standard doses, though long-term (multi-year) data remain absent [9]. Montana prescribers typically document this uncertainty during informed consent.

Patients with active malignancy are generally excluded from NMN/NR prescriptions. Providers also exercise caution with patients on immunosuppressants or chemotherapy agents due to theoretical NAD+-mediated interactions.

Prior Authorization and Documentation Requirements

Because Montana Medicaid and private insurers do not cover NMN/NR, prior authorization is not applicable for the compound itself. Patients pay cash.

However, if a patient seeks insurance coverage for the associated lab work or telehealth visits, documentation requirements apply. The telehealth visit should be billed under appropriate E/M codes (99213 or 99214 for established patients). Labs ordered for "metabolic optimization" or "age-related NAD+ decline" may be denied if the diagnosis code does not reflect a covered condition.

Providers sometimes document ICD-10 codes such as E88.9 (metabolic disorder, unspecified) or R53.83 (fatigue) to support lab coverage. This is a clinical judgment call by the prescriber.

For the compounded NMN/NR itself, the pharmacy will provide a receipt suitable for HSA/FSA reimbursement. No prior authorization form is needed since the transaction is cash-pay from the outset.